BioNTech Collaborates with OncoC4 to Co-Develop CTLA-4 Cancer Antibody

By Ayush Saxena

Pharma Deals Review: Vol 2023 Issue 3 (Table of Contents)

Published: 24 Mar-2023

DOI: 10.3833/pdr.v2023.i3.2773     ISSN: 1756-7874

Section: Research & Development



In a bid to expand its oncology portfolio, BioNTech has entered into a global licensing and collaboration agreement with OncoC4 to co-develop and commercialise a clinical stage candidate, ONC-392, as a monotherapy or combination therapy in multiple tumour indications...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details